Literature DB >> 20676227

Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Dinesh Khanna1, James R Seibold, Athol Wells, Oliver Distler, Yannick Allanore, Chris Denton, Daniel E Furst.   

Abstract

Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD ; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.

Entities:  

Year:  2010        PMID： 20676227      PMCID： PMC2911794          DOI： 10.2174/157339710791330768

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN： 1573-3971


  59 in total

1.  Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Authors:  J R Seibold; C P Denton; D E Furst; L Guillevin; L J Rubin; A Wells; M Matucci Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black
Journal:  Arthritis Rheum       Date:  2010-07

Review 2.  Cytokine directed therapy in scleroderma: rationale, current status, and the future.

Authors:  Robert W Simms; Joseph H Korn
Journal:  Curr Opin Rheumatol       Date:  2002-11       Impact factor: 5.006

3.  Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

Authors:  F H van den Hoogen; A M Boerbooms; A J Swaak; J J Rasker; H J van Lier; L B van de Putte
Journal:  Br J Rheumatol       Date:  1996-04

4.  Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Amy L Olson; Aryeh Fischer; David A Lynch; Gregory P Cosgrove; Stephen K Frankel; Richard T Meehan; Kevin K Brown
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

5.  Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts.

Authors:  Galina S Bogatkevich; Estella Gustilo; Jim C Oates; Carol Feghali-Bostwick; Russell A Harley; Richard M Silver; Anna Ludwicka-Bradley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-09-24       Impact factor: 5.464

6.  Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis.

Authors:  Philip J Clements; Michael D Roth; Robert Elashoff; Donald P Tashkin; Jonathan Goldin; Richard M Silver; Mildred Sterz; James R Seibold; Dean Schraufnagel; Robert W Simms; Marcy Bolster; Robert A Wise; Virginia Steen; M D Mayes; Kari Connelly; Mark Metersky; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2007-05-07       Impact factor: 19.103

7.  Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.

Authors:  Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements
Journal:  Arthritis Rheum       Date:  2007-05

8.  Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.

Authors:  Margaret C Garin; Kristin B Highland; Richard M Silver; Charlie Strange
Journal:  J Rheumatol       Date:  2009-01-22       Impact factor: 4.666

9.  Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.

Authors:  Nicole S L Goh; Srihari Veeraraghavan; Sujal R Desai; Derek Cramer; David M Hansell; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells
Journal:  Arthritis Rheum       Date:  2007-06

Review 10.  Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions.

Authors:  Thomas Krieg; David Abraham; Robert Lafyatis
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
View more
  10 in total

1.  Lung involvement in "stable" undifferentiated connective tissue diseases: a rheumatology perspective.

Authors:  Antonella Riccardi; Rosaria Irace; Ilaria Di Stefano; Michele Iudici; Serena Fasano; Marialuisa Bocchino; Annalisa Capaccio; Alessandro Sanduzzi; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2017-06-08       Impact factor: 2.980

Review 2.  Assessment of disease outcome measures in systemic sclerosis.

Authors:  Robert Lafyatis; Eleanor Valenzi
Journal:  Nat Rev Rheumatol       Date:  2022-07-20       Impact factor: 32.286

3.  Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.

Authors:  David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2021-08-20       Impact factor: 5.431

4.  Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.

Authors:  David Roofeh; Oliver Distler; Yannick Allanore; Christopher P Denton; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-03-05

5.  Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.

Authors:  Stylianos T Panopoulos; Vassiliki-Kalliopi Bournia; Georgia Trakada; Irene Giavri; Charalambos Kostopoulos; Petros P Sfikakis
Journal:  Lung       Date:  2013-08-08       Impact factor: 2.584

Review 6.  Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Authors:  Dinesh Khanna; James Seibold; Jonathan Goldin; Donald P Tashkin; Daniel E Furst; Athol Wells
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

7.  Management of systemic sclerosis-associated interstitial lung disease in the current era.

Authors:  Sogol Sara Amjadi; David Roofeh; Rajaie Namas; Dinesh Khanna
Journal:  Int J Rheum Dis       Date:  2020-02       Impact factor: 2.454

Review 8.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Authors:  Gabriela Kania; Michal Rudnik; Oliver Distler
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

9.  Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.

Authors:  Padmanabha D Shenoy; Manish Bavaliya; Sujith Sashidharan; Kaveri Nalianda; Sreelakshmi Sreenath
Journal:  Arthritis Res Ther       Date:  2016-06-02       Impact factor: 5.156

10.  Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.

Authors:  Dinesh Khanna; Vivek Nagaraja; Chi-Hong Tseng; Fereidoun Abtin; Robert Suh; Grace Kim; Athol Wells; Daniel E Furst; Philip J Clements; Michael D Roth; Donald P Tashkin; Jonathan Goldin
Journal:  Arthritis Res Ther       Date:  2015-12-23       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.